Bisoprolol Global Market Report 2026

Bisoprolol is a medication classified as a beta-blocker that aids in controlling high blood pressure, heart failure, and chest pain (angina). It functions by inhibiting the effects of adrenaline on the heart, decreasing heart rate and blood pressure, which lessens the heart's workload.

The primary forms of bisoprolol include tablets and capsules. The tablet form of bisoprolol is a solid, oral medication intended to manage cardiovascular conditions, providing a convenient and easy-to-use option for patients. It is generally prescribed in specific doses that enable controlled release of the medication over time. The distribution channels consist of hospital pharmacies, retail pharmacies, and others, for uses such as high blood pressure, coronary heart disease, angina pectoris, and more.

Tariffs have impacted the bisoprolol market by increasing the cost of imported active pharmaceutical ingredients, excipients, and pharmaceutical packaging materials used in tablet and capsule production. These cost pressures have been most pronounced in asia-pacific and europe, where a significant portion of bisoprolol manufacturing and raw material sourcing occurs. Hospital and retail pharmacy channels have faced pricing and margin pressures due to higher production costs. However, tariffs have also encouraged domestic manufacturing of cardiovascular drugs, supporting local supply chains and improving long-term availability of bisoprolol products.

The bisoprolol market research report is one of a series of new reports from The Business Research Company that provides bisoprolol market statistics, including bisoprolol industry global market size, regional shares, competitors with a bisoprolol market share, detailed bisoprolol market segments, market trends and opportunities, and any further data you may need to thrive in the bisoprolol industry. This bisoprolol market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bisoprolol market size has grown strongly in recent years. It will grow from $2.17 billion in 2025 to $2.35 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to high incidence of hypertension, established clinical efficacy of beta-blockers, aging population, hospital-based cardiac care growth, widespread physician prescribing.

The bisoprolol market size is expected to see strong growth in the next few years. It will grow to $3.26 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to rising cardiovascular disease burden, increasing access to generic medicines, growth in outpatient cardiac management, expansion of pharmacy networks, improved treatment adherence programs. Major trends in the forecast period include rising prevalence of cardiovascular disorders, growing use of beta-blockers in chronic care, increased adoption of generic cardiovascular drugs, expansion of retail and hospital pharmacies, higher focus on long-term blood pressure management.

The rising prevalence of hypertension is expected to drive the growth of the bisoprolol market in the coming years. Hypertension is a medical condition marked by consistently high blood pressure levels above the normal physiological range. Its prevalence is increasing due to sedentary lifestyles and growing obesity rates. The bisoprolol market aids in hypertension management by lowering blood pressure, reducing cardiac workload, and enhancing blood flow. For example, in February 2024, the Singapore Ministry of Health, a Singapore-based government health authority, reported that the prevalence of hypertension among adults reached 36.1% in 2023, up from 33.0% in 2022, reflecting a notable year-on-year rise. Consequently, the increasing prevalence of hypertension is fueling the growth of the bisoprolol market.

Major companies in the bisoprolol market are concentrating on developing innovative approaches, such as fixed-dose combinations and extended-release formulations, to enhance patient adherence, improve cardiovascular outcomes, and overcome the limitations of traditional therapies. Fixed-dose combinations refer to medications that incorporate two or more active drugs in a single tablet to simplify treatment, while extended-release formulations are designed to release the medication gradually over time, providing longer-lasting effects and reducing dosing frequency. For example, in June 2025, Cadila Pharmaceuticals Limited, an India-based pharmaceutical company, introduced Biscado (Bisoprolol) in India, entering the beta-blocker therapy segment for cardiovascular disease management. It is a highly cardioselective beta-1 adrenergic blocker indicated for the treatment of high blood pressure, angina, and chronic heart failure by lowering heart rate and blood pressure to reduce strain on the heart. Clinical studies support its effectiveness, demonstrating significant reductions in mortality, sudden cardiac death, and hospitalizations for heart failure. Biscado is available as a once-daily dose and in fixed-dose combinations with other antihypertensive drugs, aligning with global cardiovascular treatment guidelines and improving patient adherence in India.

In April 2023, SK Capital Partners LP, a US-based private investment firm focused on specialty materials, chemicals, and pharmaceuticals, acquired Apotex Inc. for an undisclosed amount. This acquisition bolsters Apotex's ability to expand its global operations by utilizing SK Capital's operational expertise and resources to drive growth and innovation. It also strengthens Apotex's capacity to provide high-quality, affordable medicines worldwide through enhanced manufacturing, increased R&D investment, and strategic market expansion. Apotex Inc. is a Canada-based pharmaceutical company and manufacturer of bisoprolol.

Major companies operating in the bisoprolol market are Merck & Co. Inc., Abbott Healthcare Pvt Ltd, Novartis AG, Teva Pharmaceutical Industries Ltd, Aurobindo Pharma Limited, Intas Pharmaceuticals Limited, Cipla Limited, Hikma Pharmaceuticals, Lupin Limited, Dr. Reddy's Laboratories Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Limited, Ipca Laboratories Limited, Medreich Limited, Alembic Pharmaceuticals Limited, Accord Healthcare Limited, Zydus Lifesciences Limited, Zentiva Group, Taj Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Suanfarma, Rusan Healthcare Limited, VHB Lifesciences Limited, Synnat Pharmaceuticals, Vidakem Lifesciences Pvt Ltd, Pluviaendo Pharmaceuticals

North America was the largest region in the bisoprolol market in 2025. The regions covered in the bisoprolol market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the bisoprolol market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bisoprolol market consists of sales of generic medicine, extended-release tablets, and oral solutions. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bisoprolol Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses bisoprolol market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for bisoprolol ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The bisoprolol market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Tablet; Capsule
• 2) By Distribution Channels: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
• 3) By Application: High Blood Pressure; Coronary Heart Disease; Angina Pectoris; Other Applications
• Subsegments:
• 1) By Tablet: Immediate-Release Tablets; Extended-Release Tablets
• 2) By Capsule: Immediate-Release Capsules; Extended-Release Capsules; Hard Gelatin Capsules
• Companies Mentioned: Merck & Co. Inc.; Abbott Healthcare Pvt Ltd; Novartis AG; Teva Pharmaceutical Industries Ltd; Aurobindo Pharma Limited; Intas Pharmaceuticals Limited; Cipla Limited; Hikma Pharmaceuticals; Lupin Limited; Dr. Reddy's Laboratories Limited; Glenmark Pharmaceuticals Limited; Alkem Laboratories Limited; Ipca Laboratories Limited; Medreich Limited; Alembic Pharmaceuticals Limited; Accord Healthcare Limited; Zydus Lifesciences Limited; Zentiva Group; Taj Pharmaceuticals Limited; Torrent Pharmaceuticals Limited; Suanfarma; Rusan Healthcare Limited; VHB Lifesciences Limited; Synnat Pharmaceuticals; Vidakem Lifesciences Pvt Ltd; Pluviaendo Pharmaceuticals
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.